Maynard Um
-
-
-
-
-
-
-
Brookline Capital Markets Starts Revolution (RVMD) at Buy
-
-
-
-
-
-
-
Revolution (RVMD) PT Raised to $260 at Oppenheimer
-
-
-
-
-
-
-
Revolution Medicines, Inc. (RVMD) Misses Q2 EPS by 110c
-
-
-
-
-
-
-
Revolution Medicines R&D chief to step down ahead of 2027 retirement
-
-
-
-
-
-
-
Revolution (RVMD) Reiterated at Buy by Stifel
-
-
-
-
-
-
-
TD Cowen Reiterates Buy Rating on Revolution (RVMD)
-
-
-
-
-
-
-
Revolution (RVMD) PT Raised to $162 at RBC Capital
-
470,348 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


